ApoE – Genetic Testing

The PrecivityAD® test measures the concentrations of amyloid beta 42 and 40 (Aβ42 and Aβ40), as well as the presence of Apolipoprotein E (ApoE) isoforms in the blood. The test indicates if an individual is likely to have amyloid plaques in the brain, a hallmark of Alzheimer’s disease. ApoE4 genotype is a significant risk factor for brain amyloid accumulation and Alzheimer’s disease, and its incorporation into C₂N’s proprietary algorithm increases the accuracy of the test. Using data from 686 patients, an algorithm based on plasma Aβ42/40 ratio, ApoE genotype, and patient age improved the separation between amyloid PET positive versus amyloid PET negative patients, as compared to using the Aβ42/40 ratio alone.

For additional information about ApoE and sharing the results of ApoE genotype testing with your patients as part of the PrecivityAD® blood test, please download the ApoE overview.